Cancers (Jul 2024)
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
- Enrique Perez-Navarro,
- Vincenza Conteduca,
- Juan M. Funes,
- Jose I. Dominguez,
- Miguel Martin-Serrano,
- Paolo Cremaschi,
- Maria Piedad Fernandez-Perez,
- Teresa Alonso Gordoa,
- Albert Font,
- Sergio Vázquez-Estévez,
- Aránzazu González-del-Alba,
- Daniel Wetterskog,
- Begona Mellado,
- Ovidio Fernandez-Calvo,
- María José Méndez-Vidal,
- Miguel Angel Climent,
- Ignacio Duran,
- Enrique Gallardo,
- Angel Rodriguez Sanchez,
- Carmen Santander,
- Maria Isabel Sáez,
- Javier Puente,
- Julian Tudela,
- Cecilia Marinas,
- María Jose López-Andreo,
- Daniel Castellano,
- Gerhardt Attard,
- Enrique Grande,
- Antonio Rosino,
- Juan A. Botia,
- Jose Palma-Mendez,
- Ugo De Giorgi,
- Enrique Gonzalez-Billalabeitia
Affiliations
- Enrique Perez-Navarro
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Vincenza Conteduca
- Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy
- Juan M. Funes
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Jose I. Dominguez
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Miguel Martin-Serrano
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Paolo Cremaschi
- University College London Cancer Institute, London WC1E 6DD, UK
- Maria Piedad Fernandez-Perez
- Department of Haematology and Medical Oncology, Hospital Universitario Morales Meseguer, Instituto Murciano de Investigaciones Biosanitarias (IMIB), 30005 Murcia, Spain
- Teresa Alonso Gordoa
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
- Albert Font
- Institut Català dOncologia, Hospital Universitari Germans Trias i Pujol, 08029 Badalona, Spain
- Sergio Vázquez-Estévez
- Hospital Universitario Lucus Augusti, 27003 Lugo, Spain
- Aránzazu González-del-Alba
- Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain
- Daniel Wetterskog
- University College London Cancer Institute, London WC1E 6DD, UK
- Begona Mellado
- Medical Oncology Department, Hospital Clínic, 08036 Barcelona, Spain
- Ovidio Fernandez-Calvo
- Department of Medical Oncology, Complejo Hospitalario Universitario Ourense, 32005 Orense, Spain
- María José Méndez-Vidal
- Medical Oncology Department, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, 14004 Córdoba, Spain
- Miguel Angel Climent
- Instituto Valenciano de Oncología, 46009 Valencia, Spain
- Ignacio Duran
- Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla (IDIVAL), 39011 Santander, Spain
- Enrique Gallardo
- Medical Oncology Service, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain
- Angel Rodriguez Sanchez
- Department of Medical Oncology, University Hospital of León, 24071 León, Spain
- Carmen Santander
- Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain
- Maria Isabel Sáez
- UGCI Oncología Médica, Hospital Universitario Virgen de la Victoria, 29010 Málaga, Spain
- Javier Puente
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, 28040 Madrid, Spain
- Julian Tudela
- Department of Pathology, Hospital Morales Meseguer, 30008 Murcia, Spain
- Cecilia Marinas
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- María Jose López-Andreo
- Department of Molecular Biology, Servicio de Apoyo a la Investigación-Instituto Murciano de Investigación Biosanitaria (SAI-IMIB), Universidad de Murcia, 30100 Murcia, Spain
- Daniel Castellano
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- Gerhardt Attard
- University College London Cancer Institute, London WC1E 6DD, UK
- Enrique Grande
- Medical Oncology Department, MD Anderson Cancer Center Madrid, Universidad Francisco de Vitoria, 28223 Madrid, Spain
- Antonio Rosino
- Urology Department, Hospital Universitario Morales Meseguer, 30005 Murcia, Spain
- Juan A. Botia
- Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, 30100 Murcia, Spain
- Jose Palma-Mendez
- Departamento de Ingeniería de la Información y las Comunicaciones, Universidad de Murcia, 30100 Murcia, Spain
- Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
- Enrique Gonzalez-Billalabeitia
- Department of Medical Oncology, Instituto de Investigación Imas12, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
- DOI
- https://doi.org/10.3390/cancers16142535
- Journal volume & issue
-
Vol. 16,
no. 14
p. 2535
Abstract
The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as transcriptional profiling and immune cell ratios. We aimed to address the contribution of distinct whole blood immune cell components to the prognosis of these patients. This study analyzed pre-treatment blood samples from 152 chemotherapy-naive mCRPC patients participating in a phase 2 clinical trial (NCT02288936) and a validation cohort. We used CIBERSORT-X to quantify 22 immune cell types and assessed their prognostic significance using Kaplan–Meier and Cox regression analyses. Reduced CD8 T-cell proportions and elevated monocyte levels were substantially connected with a worse survival. High monocyte counts correlated with a median survival of 32.2 months versus 40.3 months for lower counts (HR: 1.96, 95% CI 1.11–3.45). Low CD8 T-cell levels were associated with a median survival of 31.8 months compared to 40.3 months for higher levels (HR: 1.97, 95% CI 1.11–3.5). These findings were consistent in both the trial and validation cohorts. Multivariate analysis further confirmed the independent prognostic value of CD8 T-cell counts. This study highlights the prognostic implications of specific blood immune cells, suggesting they could serve as biomarkers in mCRPC patient management and should be further explored in clinical trials.
Keywords
- prostate cancer
- castration-resistant prostate cancer (CRPC)
- enzalutamide
- whole blood
- prognostic factors